Moodys Investors Service - Regeneron Pharmaceuticals Inc. (REGN) Regeneron Pharmaceuticals, Inc.: Update following upgrade to Baa2 and continuation of positive outlook

Report

Moody's Investors Service

EUR 216.83 For Business Accounts Only

Regeneron Pharmaceuticals, Inc.: Update following upgrade to Baa2 and continuation of positive outlook

Our credit view of this issuer reflects its solid scale and very low financial leverage, tempered by limited diversity and exposure to upcoming Eylea biosimilar competition

24/02/2023 1 EN

Underlying

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. The company's commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. The company's products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.

See profile

US75886F1075 NASDAQ Stock Market United States

Provider

Moody's Investors Service

Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:

130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations

Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.

Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.

See profile

Other Reports on these Companies

GlobeNewsWire

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of t...

5h / 17m 5h / 17m 1 EN

GlobeNewsWire

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as ...

June 15, 2025 June 15, 2025 1 EN

GlobeNewsWire

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of chronic diseases in communities of color TARRYTOWN,...

June 7, 2025 June 7, 2025 1 EN

Moody's Ratings places Electric Networks of Armenia's ratings on review for downgrade

Moody's Ratings (Moody's) has today placed Electric Networks of Armenia's (ENA) Ba2 corporate family rating (CFR) and the Ba2-PD probability of default rating (PDR) on review for downgrade. Previously, the outlook was stable. RATINGS RATIONALE / FACTORS THAT COULD LEAD TO AN UPGRADE OR DOWNGRADE O...

EUR 156.11

32m 32m 1 EN

Moody's Ratings upgrades the ratings on EUR 99.1m CLO notes of St. Paul's CLO III-R Designated Activity Company

Moody's Ratings (Moody's) has upgraded the ratings on the following notes issued by St. Paul's CLO III-R Designated Activity Company: ....EUR 30,800,000 Class C-R Senior Secured Deferrable Floating Rate Notes due 2032, Upgraded to Aaa (sf); previously on Sep 12, 2024 Upgraded to Aa3 (sf) ....EUR ...

EUR 156.11

55m 55m 1 EN

Moody's Ratings affirms Dell Bank's Baa2 ratings, stable outlook

Moody's Ratings (Moody's) today affirmed the senior unsecured and long-term issuer ratings of Dell Bank International d.a.c. (DBI) of Baa2, as well as the senior unsecured MTN Programme rating of (P)Baa2 and short-term issuer ratings of Prime-2 of DBI. The outlook on the issuer remains stable. Tod...

EUR 156.11

1h / 13m 1h / 13m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Regeneron Pharmaceuticals, Inc.: Update following upgrade to Baa2 and continuation of positive outlook

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Moody's Ratings places Electric Networks of Armenia's ratings on review for downgrade

Moody's Ratings upgrades the ratings on EUR 99.1m CLO notes of St. Paul's CLO III-R Designated Activity Company

Moody's Ratings affirms Dell Bank's Baa2 ratings, stable outlook

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe